# Brandon Capital

> Brandon Capital is a VC fund backing Biotechnology and Health Care. See 80 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Melbourne, Australia
- Total investments: 80
- Last investment: Feb 2026
- Lead investor: 33%
- Fund size: $210M
- Last fund: Apr 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/brandon-capital-partners
- Website: http://www.brandoncapital.com.au

Brandon Capital is a VC fund in Melbourne focused on Biotechnology and Health Care. Brandon Capital Partners is a funds management business aiming to generate quality returns for Australia's leading superannuation funds by investing in innovative life science ventures. Our team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and our investors.

## Contacts

5 contacts available for Brandon Capital. Shizune tracks 11 team members at Brandon Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/brandon-capital-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $673k–$9.7M |
| Series A | $5.2M–$81M |
| Series B | $6.4M–$68M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 35 | 44% |
| Health Care | 27 | 34% |
| Medical | 20 | 25% |
| Therapeutics | 15 | 19% |
| Pharmaceutical | 13 | 16% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 21 | 26% |
| Seed | 12 | 15% |
| Series B | 11 | 14% |
| Funding Round | 7 | 9% |
| Venture - Series Unknown | 7 | 9% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Australia | 29 | 36% |
| United Kingdom | 8 | 10% |
| United States | 6 | 8% |
| New Zealand | 2 | 3% |
| Israel | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chris Nave | Partner, Managing Director & Co-Founder | 18 | https://shizune.co/investors/profile/chris-nave |
| Robert Daniels | Venture Partner | 0 | https://shizune.co/investors/profile/robert-daniels |
| Stephen Thompson | Partner | 8 | https://shizune.co/investors/profile/stehpen-thompson |
| Bob Soh | Senior Investment Manager | 2 | https://shizune.co/investors/profile/bob-soh |
| Darren Kelly | Entrepreneur in Residence | 0 | https://shizune.co/investors/profile/darren-kelly-d974 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OncoRes Medical | OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue.OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leadingresearchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system.With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure. | $19.2M | Venture - Series Unknown | Feb 12, 2026 |  |
| Lumonus | Lumonous is a healthcare company that offers Radiation Oncology, Radiation Therapy, and Cancer treatment technology-enabled services. | $18.2M | Series B | Nov 06, 2025 |  |
| Ena Respiratory | Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $22.4M | Series B | Oct 22, 2025 |  |
| Ena Respiratory | Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $22.4M | Series B | Oct 22, 2025 |  |
| NRG Therapeutics | NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M | Series B | Sep 08, 2025 |  |
| Vaxxas | Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $31.8M | Series D | Aug 25, 2025 |  |
| Mirugen | Mirugen is a preclinical biotechnology company identifying the optimal set of cellular instructions to ask one cell type to become another. | $2.9M | Seed | Aug 13, 2025 |  |
| Allay Therapeutics | Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $57.5M | Series D | Jun 05, 2025 |  |
| PolyActiva | PolyActiva has developed proprietary drug-polymer conjugate technology that enables site-specific drug delivery from medical device components such as ocular implants, intra-articular gel implants, and drug-eluting fibers. | $25.7M | Series C | May 30, 2025 |  |
| AdvanCell | AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $112M | Series C | Feb 03, 2025 |  |

10 of 80 investments shown.

## Co-investors
- [Medical Research Commercialisation Fund (MRCF)](https://shizune.co/investors/profile/medical-research-commercialisation-fund-mrcf) — VC Fund, 20 deals together
- [Uniseed](https://shizune.co/investors/profile/uniseed-vc) — VC Fund, 17 deals together
- [Uniseed Ventures](https://shizune.co/investors/profile/uniseed-pty) — VC Fund, 12 deals together
- [Stoic VC](https://shizune.co/investors/profile/stoic-vc-269b) — VC Fund, 8 deals together
- [Brandon BioCatalyst](https://shizune.co/investors/profile/brandon-biocatalyst) — VC Fund, 6 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Health Care Investors in Oceania](https://shizune.co/investors/health-care-investors-oceania)
- [Health Care Investors in Australia](https://shizune.co/investors/health-care-investors-australia)
- [Health Care VC Funds in Australia](https://shizune.co/investors/health-care-vc-funds-australia)
- [All Investors in Australia](https://shizune.co/investors/investors-australia)
- [All VC Funds in Australia](https://shizune.co/investors/vc-funds-australia)
- [All Investors in Oceania](https://shizune.co/investors/investors-oceania)

## FAQ

### What does Brandon Capital invest in?

Brandon Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 80 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Brandon Capital's check size?

Brandon Capital typically joins rounds of $673k–$9.7M at Seed, $5.2M–$81M at Series A and $6.4M–$68M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Brandon Capital participates in.

### How do I contact Brandon Capital?

Public channels for Brandon Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Brandon Capital?

The team at Brandon Capital includes Chris Nave (Partner, Managing Director & Co-Founder), Robert Daniels (Venture Partner) and Stephen Thompson (Partner), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co